- Home
- SBFM
as 07-26-2024 4:00pm EST
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
| Founded: | 2006 | Country: | Canada |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 6.3M | IPO Year: | N/A |
| Target Price: | $260.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -13.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $64.50 | Next Earning Date: | 08-08-2024 |
| Revenue: | $26,739,780 | Revenue Growth: | 193.30% |
| Revenue Growth (this year): | 87.97% | Revenue Growth (next year): | 125.23% |
Latest Sunshine Biopharma Inc. News
SBFM Breaking Stock News: Dive into SBFM Ticker-Specific Updates for Smart Investing
ACCESSWIRE
2 months ago
Sunshine Biopharma Reports 2024 First Quarter Results: Revenues Up 54%
ACCESSWIRE
3 months ago
Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
ACCESSWIRE
3 months ago
Sunshine Biopharma Announces Reverse Stock Split
ACCESSWIRE
4 months ago
Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023
Simply Wall St.
4 months ago
Sunshine Biopharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
ACCESSWIRE
5 months ago
Sunshine Biopharma, Inc. Announces Closing of $10.0 Million Underwritten Public Offering
ACCESSWIRE
5 months ago
Sunshine Biopharma, Inc. Announces Pricing of $10.0 Million Underwritten Public Offering
Insider Monkey
6 months ago
11 Hyper-Growth Stocks Billionaires Are Loading Up On
Compare SBFM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SBFM Sunshine Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.